Time trends and survival of marginal zone lymphoma over 25 years in Girona, Spain (1994-2018)
Auñón, Carmen (Universitat de Girona. Departament de Medicina)
Sanvisens, Arantza (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras)
Turon, Estel (Institut d'Investigació Biomèdica de Girona)
Vidal Vila, Anna (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras)
Puigdemont, Montse (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras)
Osca Gelis, Gemma (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras)
Eraso, Arantxa (Universitat de Girona. Departament de Medicina)
Marcos-Gragera, Rafael (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras)

Data:	2023
Resum:	Objective: To analyze the incidence, incidence trends, and survival of marginal zone lymphomas (MZLs) in Girona and to describe these indicators based on the location in the case of extranodal MZLs. Methods: Population-based study of MZL collected in the Girona Cancer Registry, 1994-2018. Sociodemographic data, tumor location, and stage were obtained from clinical records. Crude (CR) and age-adjusted (ASR) incidence rates expressed per 100,000 person-years (p-y) were calculated. Joinpoint regression models were used for the trend analysis according to the MZL group. Five-year observed and net survival were analyzed. Results: A total of 472 MZLs were included, 44 (9. 3%) were nodal, 288 (61. 0%) extranodal, 122 (25. 9%) splenic, and the rest (n = 18) MZL, NOS. The CR for the MZL was 2. 89 × 100,000 p-y (95% CI: 2. 63-3. 15), the ASR was 3. 26 × 100,000 p-y (95% CI: 2. 97-3. 57), and the annual percentage change (APC) was 1. 6 (95% CI: 0. 5-2. 7). The ASR for nodal MZL was 0. 30 × 100,000 p-y (95% CI: 0. 22-0. 41) and showed an APC of 2. 9% (95% CI: −16. 4-26. 6). For extranodal MZL, the ASR was 1. 98 × 100,000 p-y (95% CI: 1. 76-2. 23) and the APC was −0. 4 (95% CI: −2. 0-1. 2). The most frequent locations of this type of MZL were the gastric (35. 4%), skin (13. 2%), and respiratory system (11. 8%). The ASR of the splenic MZL was 0. 85 (95% CI: 0. 71-1. 02) with an APC of 12. 8 (95% CI: 2. 5-24. 0). The 5-year net survival of MZL was 82. 1% (95% CI: 76. 3-86. 5). Conclusions: This study reveals differences in the incidence and trend of the incidence of MZL according to the subgroup, showing a significant increase in the overall MZL mainly due to splenic MZL type.
Ajuts:	Agència de Gestió d'Ajuts Universitaris i de Recerca 2021-SGR-01511
Nota:	This work was partially funded by the Josep Carreras Leukemia Research Institute (grant number: FIJC1100) and the Agency for Management of University and Research Grants, Government of Catalonia (grant number: 2021 SGR 01511).
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Llengua:	Anglès
Document:	Article ; recerca ; Versió publicada
Matèria:	Cancer ; Epidemiology ; Hematology ; Marginal zone lymphoma ; Population-based
Publicat a:	Cancer Medicine, Vol. 12 Núm. 11 (june 2023) , p. 12343-12353, ISSN 2045-7634

DOI: 10.1002/cam4.5935
PMID: 37076996

11 p, 310.2 KB

El registre apareix a les col·leccions:
Documents de recerca > Documents dels grups de recerca de la UAB > Centres i grups de recerca (producció científica) > Ciències de la salut i biociències > Institut d'Investigació en Ciencies de la Salut Germans Trias i Pujol (IGTP) > Institut de Recerca contra la Leucèmia Josep Carreras
Articles > Articles de recerca
Articles > Articles publicats